Novo Nordisk reports 2025 sales growth, cuts 2026 outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Novo Nordisk (NVO) Tops Q4 EPS by 10c; Lowers Outlook
February 3, 2026 12:05 PM ESTNovo Nordisk (NYSE: NVO) reported Q4 EPS of $1.02, $0.10 better than the analyst estimate of $0.92. Revenue for the quarter came in at $12.53 billion versus the consensus estimate of $11.99 billion.
GUIDANCE:
Adjusted sales growth for 2026, which excludes revenue from the reversal of 340B... More
